Virtual therapy with the nmda antagonist memantine in hippocampal models of moderate to severe alzheimer’s disease, in silico trials

HIGHLIGHTS

  • who: Dariusz u015awietlik and collaborators from the Division of Biostatistics and Neural Networks, Medical University of Gdanu0301sk, Du02dbebinki, Gdansk, Poland have published the paper: Virtual Therapy with the NMDA Antagonist Memantine in Hippocampal Models of Moderate to Severe Alzheimeru2019s Disease, In Silico Trials, in the Journal: Pharmaceuticals 2022, 15, 546. of /2022/
  • what: The aim of this in silico study is a memantine therapy for Alzheimer`s disease that provides a different perspective on clinical trials;

SUMMARY

    The number of spikes of virtual hippocampal AD was significantly lower, at 1648.7 . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?